Boehringer Ingelheim reported discovery of cyclic GMP‑AMP synthase (cGAS) inhibitors with potential across autoinflammatory and fibrotic indications (f0d08b4fdbedcc05). The company’s disclosure details novel small molecules that modulate innate immune sensing via cGAS inhibition. Lead claim: the inhibitors showed biochemical potency and cellular activity consistent with suppression of cGAS–STING signaling, a pathway implicated in interferonopathies, pulmonary fibrosis, MASH, and systemic autoimmune disease. Boehringer frames these compounds as candidate starting points for disease-modifying therapies. For therapeutic R&D, these disclosures illustrate big‑pharma investment in innate immunity targets and support growing industry interest in cGAS/STING modulation for inflammatory and fibrotic disorders.